This Article
Right arrow Full Text (PDF)
Right arrow Letters to the Editor: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Letters to the Editor are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowReprints and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ELIAS, E. G.
Right arrow Articles by EVANS, J. T.
Right arrow Search for Related Content
PubMed
Right arrow Articles by ELIAS, E. G.
Right arrow Articles by EVANS, J. T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Technorati  
What's this?
Journal of Bone and Joint Surgery, 1972;54:1730-1736.
© 1972 by The Journal of Bone and Joint Surgery, Inc

Mithramycin in the Treatment of Paget's Disease of Bone

E. G. ELIAS M.D.1 and JAMES T. EVANS M.D.1

1 From the General Clinical Research Center, Department of Surgery, Roswell Park Memorial Institute, New York State Department of Health, Buffalo

Ten patients with symptomatic Paget's disease of bone were treated with mithramycin. Subjective improvement, as demonstrated by complete pain relief and increased activity, was reported by seven patients and partial pain relief was reported by two. Pain persisted in one patient with a co-existing osteogenic sarcoma. No roentgenographic changes were noticed in the involved bones after therapy. Chemically, improvement was demonstrated by reduction of levels of serum alkaline phosphatase and urinary hydroxyproline. Five patients were in positive calcium balance before mithramycin therapy and showed an increase after therapy. Mithramycin administered in the dose of twenty-five micrograms per kilogram of body weight by slow intravenous drip method, once every two to three weeks, was well tolerated and showed suppressive effects on symptomatic Paget's disease of bone, and no hepatic, renal, or myelogenous evidence of toxicity was noticed in the immediate or long-term follow-up in these patients.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
M.-H. Hou and A. H.-J. Wang
Mithramycin forms a stable dimeric complex by chelating with Fe(II): DNA-interacting characteristics, cellular permeation and cytotoxicity
Nucleic Acids Res., March 1, 2005; 33(4): 1352 - 1361.
[Abstract] [Full Text] [PDF]